ZA202208343B - Daptomycin formulation - Google Patents

Daptomycin formulation

Info

Publication number
ZA202208343B
ZA202208343B ZA2022/08343A ZA202208343A ZA202208343B ZA 202208343 B ZA202208343 B ZA 202208343B ZA 2022/08343 A ZA2022/08343 A ZA 2022/08343A ZA 202208343 A ZA202208343 A ZA 202208343A ZA 202208343 B ZA202208343 B ZA 202208343B
Authority
ZA
South Africa
Prior art keywords
daptomycin
formulation
solid
daptomycin formulation
present disclosure
Prior art date
Application number
ZA2022/08343A
Other languages
English (en)
Inventor
Fumic Barbara
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of ZA202208343B publication Critical patent/ZA202208343B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2022/08343A 2020-02-28 2022-07-26 Daptomycin formulation ZA202208343B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982945P 2020-02-28 2020-02-28
PCT/EP2021/054841 WO2021170807A1 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Publications (1)

Publication Number Publication Date
ZA202208343B true ZA202208343B (en) 2024-11-27

Family

ID=74797935

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/08343A ZA202208343B (en) 2020-02-28 2022-07-26 Daptomycin formulation

Country Status (10)

Country Link
US (1) US20230068866A1 (enExample)
EP (1) EP4110303A1 (enExample)
JP (2) JP2023516957A (enExample)
CN (2) CN118873500A (enExample)
AU (1) AU2021227095B2 (enExample)
BR (1) BR112022015571A2 (enExample)
CA (1) CA3168727A1 (enExample)
MX (1) MX2022010378A (enExample)
WO (1) WO2021170807A1 (enExample)
ZA (1) ZA202208343B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770366C2 (ru) 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
RU2770366C2 (ru) * 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
CN118873500A (zh) 2024-11-01
US20230068866A1 (en) 2023-03-02
CA3168727A1 (en) 2021-09-02
BR112022015571A2 (pt) 2022-09-27
MX2022010378A (es) 2022-09-21
AU2021227095B2 (en) 2024-02-22
AU2021227095A1 (en) 2022-08-25
JP2025142200A (ja) 2025-09-30
JP2023516957A (ja) 2023-04-21
CN115038431B (zh) 2024-08-09
CN115038431A (zh) 2022-09-09
WO2021170807A1 (en) 2021-09-02
EP4110303A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
MX2021015894A (es) Peptidos acetales para estabilizar enzimas.
PH12021551279A1 (en) Modified amine lipids
MX2023009645A (es) Composiciones para preparar productos similares al huevo libres de animales.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
ZA202309527B (en) Ionizable lipids and compositions for nucleic acid delivery
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
MX2011012181A (es) Composicion y metodo para controlar enfermedades de plantas.
MX2011012334A (es) Composicion y metodo para promover el crecimiento de raices de plantas.
MX2021006126A (es) Proceso de preparacion de una composicion tensioactiva a base de sal de ester de glicina betaina y composicion asi obtenida.
ZA202208343B (en) Daptomycin formulation
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
PH12021551922A1 (en) Afabicin formulation, method for making the same
MX2025005727A (es) Composiciones para el cuidado bucal
MX2011012174A (es) Composicion y metodo para controlar plagas.
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
MY207295A (en) Method for preparing a composition comprising cetylated fatty acids
MX392143B (es) Composiciones cosméticas para el cuidado de la piel.
MX2021011553A (es) Producto para el cuidado bucal y metodos para uso y fabricacion de este.
PH12022552789A1 (en) Laminarin based formulation for agricultural applications
PH12017502323A1 (en) Novel xylanase
MX2019006122A (es) Metodo de hornear.
MX370065B (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
EA201692454A1 (ru) Твердая фосфатная соль и способ ее получения
PH12022550008A1 (en) Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid